Patents by Inventor Philip Christopher Buxton
Philip Christopher Buxton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075013Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: October 31, 2023Publication date: March 7, 2024Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11872214Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: January 16, 2024Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11844783Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: December 14, 2022Date of Patent: December 19, 2023Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20230372438Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: ApplicationFiled: October 21, 2022Publication date: November 23, 2023Applicant: SciDose Pharma LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20230115693Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: December 14, 2022Publication date: April 13, 2023Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20230115164Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: December 14, 2022Publication date: April 13, 2023Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11497789Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: GrantFiled: December 11, 2020Date of Patent: November 15, 2022Assignee: SCIDOSE PHARMA, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20210393594Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: August 26, 2021Publication date: December 23, 2021Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11103483Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: July 12, 2019Date of Patent: August 31, 2021Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20210236592Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: ApplicationFiled: December 11, 2020Publication date: August 5, 2021Applicant: SciDose Pharma LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 10864250Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: GrantFiled: July 16, 2019Date of Patent: December 15, 2020Assignee: SCIDOSE PHARMA LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20190350904Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: July 12, 2019Publication date: November 21, 2019Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20190336570Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: ApplicationFiled: July 16, 2019Publication date: November 7, 2019Applicant: SciDose, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 10376559Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: GrantFiled: January 13, 2017Date of Patent: August 13, 2019Assignee: SCIDOSE, LLCInventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20180296535Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: June 22, 2018Publication date: October 18, 2018Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20180296536Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: June 22, 2018Publication date: October 18, 2018Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 10010533Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: February 14, 2017Date of Patent: July 3, 2018Assignee: EAGLE PHARMACEUTICALS, INC.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20180000789Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: ApplicationFiled: February 14, 2017Publication date: January 4, 2018Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Publication number: 20170232015Abstract: Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing compositions of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C.Type: ApplicationFiled: April 28, 2017Publication date: August 17, 2017Inventors: Nagesh R. Palepu, Philip Christopher BUXTON
-
Publication number: 20170224767Abstract: Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.Type: ApplicationFiled: January 13, 2017Publication date: August 10, 2017Inventors: Nagesh R. Palepu, Philip Christopher Buxton